Alpha Tau (DRTS) announced the treatment of the first patient in ACAPELLA, the company’s European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma who have completed first-line mFOLFIRINOX chemotherapy. The procedure was performed at CHU Grenoble Alpes by Pr. Gael Roth, Lead Investigator of ACAPELLA, and his team, marking the first use of Alpha DaRT for pancreatic cancer in Europe.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Wins First DDW Oral Slot for Alpha DaRT Pancreatic Cancer Data
- Alpha Tau is Firing on All Cylinders: Japan Approval, 5 US Trials, And Now Pancreatic Data Heads to DDW
- Alpha Tau price target raised to $9 from $7 at Citi
- Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses
- Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year